Q1 Earnings Forecast for XENE Issued By HC Wainwright

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – HC Wainwright issued their Q1 2025 earnings estimates for shares of Xenon Pharmaceuticals in a report issued on Wednesday, November 13th. HC Wainwright analyst D. Tsao expects that the biopharmaceutical company will post earnings per share of ($0.88) for the quarter. HC Wainwright has a “Buy” rating and a $53.00 price objective on the stock. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.10) per share. HC Wainwright also issued estimates for Xenon Pharmaceuticals’ Q2 2025 earnings at ($0.89) EPS, Q3 2025 earnings at ($0.90) EPS and Q4 2025 earnings at ($0.91) EPS.

Several other equities research analysts also recently commented on XENE. Royal Bank of Canada restated an “outperform” rating and issued a $55.00 target price on shares of Xenon Pharmaceuticals in a research note on Tuesday, September 3rd. Needham & Company LLC reissued a “buy” rating and set a $60.00 price objective on shares of Xenon Pharmaceuticals in a report on Wednesday. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $65.00 price target on shares of Xenon Pharmaceuticals in a research note on Friday, August 9th. William Blair raised Xenon Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. Finally, Wedbush decreased their price objective on Xenon Pharmaceuticals from $50.00 to $49.00 and set an “outperform” rating for the company in a research report on Friday, August 9th. Eleven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Xenon Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $57.45.

Xenon Pharmaceuticals Trading Down 0.5 %

Shares of Xenon Pharmaceuticals stock opened at $41.75 on Friday. The company’s fifty day simple moving average is $41.14 and its 200-day simple moving average is $40.35. The company has a market cap of $3.18 billion, a price-to-earnings ratio of -14.80 and a beta of 1.25. Xenon Pharmaceuticals has a 1 year low of $28.10 and a 1 year high of $50.99.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($0.82) by $0.01. During the same quarter in the prior year, the business posted ($0.73) EPS.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of XENE. Blue Trust Inc. boosted its position in shares of Xenon Pharmaceuticals by 174.7% during the third quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 641 shares during the last quarter. nVerses Capital LLC bought a new stake in shares of Xenon Pharmaceuticals in the third quarter valued at $102,000. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Xenon Pharmaceuticals by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 487 shares during the period. Quarry LP raised its stake in shares of Xenon Pharmaceuticals by 207.7% in the second quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company’s stock valued at $156,000 after buying an additional 2,700 shares during the period. Finally, EntryPoint Capital LLC bought a new stake in shares of Xenon Pharmaceuticals in the first quarter valued at $195,000. Hedge funds and other institutional investors own 95.45% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.